An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsEvidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancerEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysisPanitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS StatusSystematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.Management of stage IV rectal cancer: palliative options.Biological agents in gastrointestinal cancers: adverse effects and their management.Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancerEfficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsHave we overestimated the benefit of human(ized) antibodies?Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisDetection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotypingSafety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer.Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer.The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials.Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases.Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic AnalysisY90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative studyKRAS mutations and subtyping in colorectal cancer in Jordanian patients.Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.Immunotherapy for gastrointestinal malignancies.Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft modelsSystemic cancer therapy: achievements and challenges that lie aheadManagement of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendationsClinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.Systemic and targeted therapy for advanced colon cancer.EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab.Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors.
P2860
Q26738810-5791F09E-DFA9-4CD7-9785-1B405327F6F4Q26752747-E507AF27-696A-4EF5-9750-D364527CEEA1Q26771952-4C13CC82-EBD1-4446-B27E-30B740925A7BQ26777704-544814C4-14CB-426E-9F74-4CC49EE21E74Q26796348-7A0DA8C8-11B1-43F3-881E-65AA5EA65B64Q26865056-6273A306-C021-4B5F-A4E2-0ABAC3CD798AQ28082816-340990A0-A3F5-44DC-92CC-39FD4BECB1ADQ31048123-1A52599C-1034-4591-B3E5-24487A6064D7Q33849034-3D09536B-27EA-439A-88D9-055D8DBC0298Q33895581-8205075F-596A-417D-B73E-82F6C02FF88AQ33983656-24287C82-E9BC-4ABB-B3C3-EA9564C7B7DBQ33983663-947CF77E-F970-46D5-B61E-DF614E69A7E8Q34059726-90DB692E-22DE-4168-9590-60A1AE74C656Q34110768-30C8B617-2063-4F66-8551-02DD8DA470E9Q34142714-35861CDB-CCA2-4C15-9EEB-1BA0968BB619Q34239801-8F750349-1DA7-40FA-BB0F-EBC52C632F1CQ34272887-F1CB7CA3-A5DA-4935-8C05-E9CC6AEC1416Q34760933-2B21E7F8-33DB-4308-9292-2DE94E77AA9FQ34923902-DA1478D4-EA01-4C47-B449-BD5EFA1B32BFQ34960017-00C5905C-57F8-480A-A3E5-30B926E75153Q35173455-8CE7D663-4A3C-4038-81B8-CB73F66587D3Q35328438-0E6B2D55-B32B-4526-8785-F960886A1441Q35913241-A4DF73D8-5FED-4E77-B3FD-195B064BBAB5Q35998470-D261E35B-D116-40BC-88A7-D3F16200C0C9Q36039967-EDEE730B-542A-453A-8C77-9A8A22EDCFAAQ36083302-8B02EA60-88BA-47E7-A978-44E4B9EC8EB6Q36244233-97AE5F86-B4CC-4C9A-9480-6651E0A9370CQ36424058-849FC018-86CD-4006-9CB9-3FA3A73573DBQ36537873-E8399E93-B4B3-4D3A-AB98-6C1B66B9E3EAQ36602174-1FE1A2BE-234C-4E13-96E8-EB2B4C5F7C9BQ36610680-405A72D2-B707-4B1D-BE09-9E4C9E65B6C6Q36629392-A9D592A8-F386-4A5B-A4DB-A2A0DDA4CFE3Q36821958-3D805FCD-89E4-4FCC-88B3-84AE904F67FFQ37102073-749E829C-7054-469F-B26E-CABB07718324Q37181068-98287117-0709-4DB2-9210-4996D4D7AB12Q37316037-192CBA46-6FEA-4EE8-B369-421C1851B6F6Q37345922-0B67F2D5-D066-4C33-A5F9-A1586D9DF8F0Q37561771-27BAE616-939C-48F3-B755-450F601DA000Q37589223-7B8DB8BB-4C6B-43C7-9770-31B7D17058DAQ37887819-AAC5B05A-589A-4409-B212-5F96339CD1F1
P2860
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
An open-label, single-arm stud ...... tory to standard chemotherapy.
@en
An open-label, single-arm stud ...... tory to standard chemotherapy.
@nl
type
label
An open-label, single-arm stud ...... tory to standard chemotherapy.
@en
An open-label, single-arm stud ...... tory to standard chemotherapy.
@nl
prefLabel
An open-label, single-arm stud ...... tory to standard chemotherapy.
@en
An open-label, single-arm stud ...... tory to standard chemotherapy.
@nl
P2093
P356
P1433
P1476
An open-label, single-arm stud ...... tory to standard chemotherapy.
@en
P2093
E Van Cutsem
P356
10.1093/ANNONC/MDM399
P50
P577
2007-09-04T00:00:00Z